|
1
|
Gaona-Luviano P, Medina-Gaona LA and
Magaña-Pérez K: Epidemiology of ovarian cancer. Chin Clin Oncol. 9.
pp. 472020, View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Islami F, Siegel RL, Ward EM and
Jemal A: Global cancer in women: Burden and trends. Cancer
Epidemiol Biomarkers Prev. 26:444–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bach LA: IGF-binding proteins. J Mol
Endocrinol. 61:T11–T28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Firth SM and Baxter RC: Cellular actions
of the insulin-like growth factor binding proteins. Endocr Rev.
23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baxter RC: IGF binding proteins in cancer:
Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bach LA, Fu P and Yang Z: Insulin-like
growth factor-binding protein-6 and cancer. Clin Sci (Lond).
124:215–229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Walker G, MacLeod K, Williams ARW, Cameron
DA, Smyth JF and Langdon SP: Insulin-like growth factor binding
proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine
responsiveness in patients with ovarian cancer. Clin Cancer Res.
13:1438–1444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bahrani-Mostafavi Z, Tickle TL, Zhang J,
Bennett KE, Vachris JC, Spencer MD, Mostafavi MT and Tait DL:
Correlation analysis of HOX, ERBB and IGFBP family gene expression
in ovarian cancer. Cancer Invest. 26:990–998. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Z and Bach LA: Differential effects
of insulin-like growth factor binding protein-6 (IGFBP-6) on
migration of two ovarian cancer cell lines. Front Endocrinol
(Lausanne). 5:2312015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amutha P and Rajkumar T: Role of
insulin-like growth factor, insulin-like growth factor receptors,
and insulin-like growth factor-binding proteins in ovarian cancer.
Indian J Med Paediatr Oncol. 38:198–206. 2017.PubMed/NCBI
|
|
11
|
Oliva CR, Halloran B, Hjelmeland AB,
Vazquez A, Bailey SM, Sarkaria JN and Griguer CE: IGFBP6 controls
the expansion of chemoresistant glioblastoma through paracrine
IGF2/IGF-1R signaling. Cell Commun Signal. 16:612018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langdon SP, Lawrie SS, Hay FG, Hawkes MM,
McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC and Smyth
JF: Characterization and properties of nine human ovarian
adenocarcinoma cell lines. Cancer Res. 48:6166–6172.
1988.PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Avolio R, Järvelin AI, Mohammed S,
Agliarulo I, Condelli V, Zoppoli P, Calice G, Sarnataro D, Bechara
E, Tartaglia GG, et al: Protein syndesmos is a novel RNA-binding
protein that regulates primary cilia formation. Nucleic Acid Res.
46:12067–12086. 2018.PubMed/NCBI
|
|
15
|
Zhao B. Erwin A and Xue B: How many
differentially expressed genes: A perspective from the comparison
of genotypic and phenotypic distances. Genomics. 110:67–73. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liberzon A, Subramanian A, Pinchback R,
Thorvaldsdóttir H, Tamayo P and Mesirov JP: Molecular signatures
database (MSigDB) 3.0. Bioinformatics. 27:1739–1740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
R Core Team R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: 2020
|
|
20
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartha A and Győrffy B: TNMplot.com: A web
tool for the comparison of gene expression in normal, tumor and
metastatic tissues. Int J Mol Sci. 22:26222021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Research.
45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and
Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med.
19:1997–2007. 2020.PubMed/NCBI
|
|
24
|
Fujioka S, Son K, Onda S, Schmidt C,
Scrabas GM, Okamoto T, Fujita T, Chiao PJ and Yanaga K:
Desensitization of NFκB for overcoming chemoresistance of
pancreatic cancer cells to TNF-α or paclitaxel. Anticancer Res.
32:4813–4821. 2012.PubMed/NCBI
|
|
25
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Drivdahl RH, Sprenger C, Trimm K and
Plymate SR: Inhibition of growth and increased expression of
insulin-like growth factor-binding protein-3 (IGFBP-3) and −6 in
prostate cancer cells stably transfected with antisense IGFBP-4
complementary deoxyribonucleic acid. Endocrinology. 142:1990–1998.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nordqvist AC and Mathiesen T: Expression
of IGF-II, IGFBP-2, −5, and −6 in meningiomas with different brain
invasiveness. J Neurooncol. 57:19–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cacalano NA, Le D, Paranjpe A, Wang MY,
Fernandez A, Evazyan T, Park NH and Jewett A: Regulation of IGFBP6
gene and protein is mediated by the inverse expression and function
of c-jun N-terminal kinase (JNK) and NFkappaB in a model of oral
tumor cells. Apoptosis. 13:1439–1449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gunawardana CG, Kuk C, Smith CR, Batruch
I, Soosaipillai A and Diamandis EP: Comprehensive analysis of
conditioned media from ovarian cancer cell lines identifies novel
candidate markers of epithelial ovarian cancer. J Proteome Res.
8:4705–4713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng R, Chen W, Xia W, Zheng J and Zhou
Q: The prognostic values of the insulin-like growth factor binding
protein family in ovarian cancer. Biomed Res Int. 2020:76587822020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pavlakis G, Mountzios G, Terpos E,
Leivaditou A, Papadopoulos G and Papasavas P: Recurrent ovarian
cancer metastatic to the sternum, costae, and thoracic wall after
prolonged treatment with platinum-based chemotherapy: A case report
and review of the literature. Int J Gynecol Cancer. 16 (Suppl
1):S299–S303. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T and Johnson N: Neoadjuvant chemotherapy or primary
surgery in stage IIIC or IV ovarian cancer. N Engl J Med.
363:943–953. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lisio MA, Fu L, Goyeneche A, Gao ZH and
Telleria C: High-grade serous ovarian cancer: Basic Sciences,
clinical and therapeutic standpoints. Int J Mol Sci. 20:9522019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bach LA: Recent insights into the actions
of IGFBP-6. J Cell Commun Signal. 9:189–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liso A, Capitanio N, Gerli R and Conese M:
From fever to immunity: A new role for IGFBP-6? J Cell Mol Med.
22:4588–4596. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bach LA: Current ideas on the biology of
IGFBP-6: More than an IGF-II inhibitor? Growth Horm IGF Res.
30-31:81–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu P, Liang GJ, Khot SS, Phan R and Bach
LA: Cross-talk between MAP kinase pathways is involved in
IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell
migration. J Cell Physiol. 224:636–643. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Plotnikov A, Zehorai E, Procaccia S and
Seger R: The MAPK cascades: Signaling components, nuclear roles and
mechanisms of nuclear translocation. Biochim Biophys Acta.
1813:1619–1633. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Amoroso MR, Matassa DS, Agliarulo I,
Avolio R, Maddalena F, Condelli V, Landriscina M and Esposito F:
Stress-adaptive response in ovarian cancer drug resistance: Role of
TRAP1 in oxidative metabolism-driven inflammation. Adv Protein Chem
Struct Biol. 108:163–198. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ and Sun
WJ: Autocrine production of interleukin-6 confers cisplatin and
paclitaxel resistance in ovarian cancer cells. Cancer Lett.
295:110–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Matassa DS, Amoroso MR, Lu H, Avolio R,
Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V,
Agliarulo I, et al: Oxidative metabolism drives
inflammation-induced platinum resistance in human ovarian cancer.
Cell Death Differ. 23:1542–1554. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Farolfi A, Scarpi E, Greco F, Bergamini A,
Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, et
al: Inflammatory indexes as predictive factors for platinum
sensitivity and as prognostic factors in recurrent epithelial
ovarian cancer patients: A MITO24 retrospective study. Sci Rep.
10:181902020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao Q, Zhong J, Lu P, Feng X, Han Y, Ling
C, Guo W, Zhou W and Yu F: DOCK4 is a platinum-chemosensitive and
prognostic-related biomarker in ovarian cancer. PPAR Res.
2021:66298422021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Grabosch S, Bulatovic M, Zeng F, Ma T,
Zhang L, Ross M, Brozick J, Fang Y, Tseng G, Kim E, et al:
Cisplatin-induced immune modulation in ovarian cancer mouse models
with distinct inflammation profiles. Oncogene. 38:2380–2393. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Browning L, Patel MR, Horvath EB, Tawara K
and Jorcyk CL: IL-6 and ovarian cancer: Inflammatory cytokines in
promotion of metastasis. Cancer Manag Res. 10:6685–6693. 2018.
View Article : Google Scholar : PubMed/NCBI
|
